CarelabsLtd Full Year 2024 Earnings: ₩1,045 loss per share (vs ₩1,289 loss in FY 2023)

Simply Wall St

March 20, 2025

CarelabsLtd (KOSDAQ:263700) Full Year 2024 Results

Key Financial Results

Revenue: ₩83.2b (up 1.7% from FY 2023).
Net loss: ₩20.3b (loss narrowed by 17% from FY 2023).
₩1,045 loss per share (improved from ₩1,289 loss in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

earnings-and-revenue-history — KOSDAQ:A263700 Earnings and Revenue History March 20th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

CarelabsLtd shares are down 2.4% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with CarelabsLtd (at least 1 which shouldn't be ignored), and understanding these should be part of your investment process.

If you're looking to trade CarelabsLtd, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.